DeutschMarina Babic – Cac: Immune checkpoints as therapeutic targets in inflammation
Event date
Thursday, 24 January 2019 || Time: 14:00
Delineation
Immune response is a result of a very delicate balance between activating and inhibitory signals provided by the molecules expressed on the surface of immune cells. While too little inflammation results in the increased susceptibility to pathogens and possible outgrowth of malignant cells, the consequence of too much inflammation is autoimmunity and immune pathology. In the recent decade, cancer therapy was revolutionized by the development of drugs targeting immune checkpoints, receptors such as CTLA-4 and PD-1, thus interrupting the inhibitory signal and unleashing the T cell mediated anti-tumor response. This lecture will give an overview on the current progress in targeting T cell checkpoints, both co-stimulatory and inhibitory receptors, as well as how the experience from treating cancer with checkpoint blockade could be used as a therapeutic approach in autoimmune rheumatic diseases.
Event venue
when: 14:00-15:00, weekly, every Thursday
where: DRFZ, Seminar room 3, Charitéplatz 1
visitors: Virchowweg 12
Click here to download the map from Google Maps
Registration & Contact
• Are you familiar with chronic inflammatory diseases?
• Have you heard that any organ can be affected?
• Joints, skin, kidneys, nerves, intestines – all?
• understand one inflammatory disease – cure them all?
…. these and further topics will be covered in the new Lecture Series given by our Postdoc Fellows.
Topics
miRNA +++ drug discovery +++ imaging +++ cancer +++ RNA-based gene regulation +++ immune checkpoints as therapeutic targets +++ T cells +++ mass cytometry ++ plasma cell targeting +++ RA and cardiovascular disease +++ optical ethods +++ stromal niches
Speakers
Stefan Frischbutter +++ Patrick Maschmeyer +++ Randall Lindquist +++ Gitta Heinz +++ Marina Babic-Cac +++ Shintaro Hoyjo +++ Axel Schulz +++ Laleh Khodadadi +++ Yvette Meissner +++ Asylkhan Rakhymzhan +++ Daniel Schulz
In the ScienceCampus we aim at transferring research and therapeutic concepts from one disease to another – across disciplines – for a fast translation into the clinic.